![1H-Benzimidazole,2-[(2,4-dichlorophenyl)methyl]-](/ProductImageEN/2022-02/Large/4d76987b-e71b-4294-b838-a42b63f69189.png)
![1H-Benzimidazole,2-[(2,4-dichlorophenyl)methyl]-](/ProductImageEN/2022-02/Small/4d76987b-e71b-4294-b838-a42b63f69189.png)
Product Details
| Product Name: 1H-Benzimidazole,2-[(2,4-dichlorophenyl)methyl]- | CAS No.: 154660-96-5 |
| Min. Order: 1gram | Purity: 99% |
| Supply Ability: 10kg | Release date: 2025/12/25 |
ZHEJIANG BIOLOGY AND TECHNOLOGY CO., LTD. is a modern professional high-tech enterprise, which is specializing in generic APIs and pharmaceutical intermediates. especially in peptide, peptide reagents and related products. We mainly works on research and development the health product of human and animals. We have an advanced team to make research and develop the new product
Company Profile Introduction
ZHEJIANG BIOLOGY AND TECHNOLOGY CO., LTD. is a modern professional high-tech enterprise, which is specializing in generic APIs and pharmaceutical intermediates. especially in peptide, peptide reagents and related products. We mainly works on research and development the health product of human and animals. We have an advanced team to make research and develop the new product. our main products included HGH, IGF, VGF, NGF, SOD1, GHRP-6, CJC-1295, MT2, HCG, MGF, PEG-MGF, PT-141, jwh AM some Medicines Intermediates and Etc...
Welcome to inquiry. All the lupharm staff sincerely hope to service for you.!
You may like
-
CAS:947504-99-6
-
CAS:5468-66-6
-
CAS:213133-77-8
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
airuikechemical co., ltd.
|
2024-12-24 | |||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 | ||
| $45.00 |
Longyan Tianhua Biological Technology Co., Ltd
|
2020-11-16 | ||
| $2.00 |
VIP9Y
|
Career Henan Chemical Co
|
2019-07-06 | |
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 |
China- Since: 2020-10-24
- Address: No. 80 Tianyu Community, Jiangshan City, Quzhou City, Zhejiang Province, China
INQUIRY